CA2766899C - Compositions and methods for diagnosing and/or treating influenza infection - Google Patents

Compositions and methods for diagnosing and/or treating influenza infection Download PDF

Info

Publication number
CA2766899C
CA2766899C CA2766899A CA2766899A CA2766899C CA 2766899 C CA2766899 C CA 2766899C CA 2766899 A CA2766899 A CA 2766899A CA 2766899 A CA2766899 A CA 2766899A CA 2766899 C CA2766899 C CA 2766899C
Authority
CA
Canada
Prior art keywords
fold
polypeptide
seq
binding
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2766899A
Other languages
English (en)
French (fr)
Other versions
CA2766899A1 (en
Inventor
Akila Jayaraman
Karthik Viswanathan
Rahul Raman
Zachary H. Shriver
Ram Sasisekharan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Institute of Technology
Original Assignee
Massachusetts Institute of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute of Technology filed Critical Massachusetts Institute of Technology
Publication of CA2766899A1 publication Critical patent/CA2766899A1/en
Application granted granted Critical
Publication of CA2766899C publication Critical patent/CA2766899C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2766899A 2009-07-02 2010-07-02 Compositions and methods for diagnosing and/or treating influenza infection Active CA2766899C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22288909P 2009-07-02 2009-07-02
US61/222,889 2009-07-02
PCT/US2010/040978 WO2011003100A2 (en) 2009-07-02 2010-07-02 Compositions and methods for diagnosing and/or treating influenza infection

Publications (2)

Publication Number Publication Date
CA2766899A1 CA2766899A1 (en) 2011-01-06
CA2766899C true CA2766899C (en) 2021-05-04

Family

ID=43411785

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2766899A Active CA2766899C (en) 2009-07-02 2010-07-02 Compositions and methods for diagnosing and/or treating influenza infection

Country Status (7)

Country Link
US (2) US9278998B2 (https=)
EP (1) EP2448596B1 (https=)
JP (2) JP5886194B2 (https=)
AU (1) AU2010266129B2 (https=)
CA (1) CA2766899C (https=)
ES (1) ES2566361T3 (https=)
WO (1) WO2011003100A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9278998B2 (en) 2009-07-02 2016-03-08 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection
WO2011094445A1 (en) * 2010-01-27 2011-08-04 Massachusetts Institute Of Technology Engineered polypeptide agents for targeted broad spectrum influenza neutralization
WO2012040406A2 (en) 2010-09-21 2012-03-29 Massachusetts Institute Of Technology Influenza treatment and/or characterization; human-adapted ha polypeptides; vaccines
BR112013007946B1 (pt) 2010-10-04 2022-07-12 Massachusetts Institute Of Technology Composições farmacêuticas e imunogênicas compreendendo polipeptídeos de hemaglutinina
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US10022434B2 (en) 2013-03-15 2018-07-17 The Trustees Of The University Of Pennsylvania Influenza nucleic acid molecules and vaccines made therefrom
WO2014179464A1 (en) * 2013-04-30 2014-11-06 Massachusetts Institute Of Technology Human adaptation of h3 influenza
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
US11781112B2 (en) 2016-03-06 2023-10-10 Kareem Thomas Robinson Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法
BR112022021208A8 (pt) * 2020-04-22 2023-02-23 Medicago Inc Supraestrutura compreendendo hemaglutinina de influenza modificada com interação reduzida com ácido siálico

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4692411A (en) 1983-09-06 1987-09-08 Ghose Rabindra N Separation of specific biological cells by a biochemical filter
US5698390A (en) 1987-11-18 1997-12-16 Chiron Corporation Hepatitis C immunoassays
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
US6085349A (en) * 1997-08-27 2000-07-04 Qualcomm Incorporated Method for selecting cyclic redundancy check polynomials for linear coded systems
JP5008244B2 (ja) 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
US8592197B2 (en) 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2006108226A1 (en) 2005-04-12 2006-10-19 The University Of Queensland Vaccine delivery system
SG169996A1 (en) 2006-02-16 2011-04-29 Us Gov Health & Human Serv Antiviral agents and vaccines against influenza
US9101578B2 (en) 2006-05-01 2015-08-11 Technovax, Inc. Polyvalent influenza virus-like particle (VLP) compositions
US8778353B2 (en) 2006-05-01 2014-07-15 Technovax, Inc. Influenza virus-like particle (VLP) compositions
EP1998814A4 (en) 2006-05-11 2010-06-16 Novavax Inc NEW VACCINES AGAINST INFLUENZA M2
US9511134B2 (en) * 2006-05-18 2016-12-06 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2008005777A2 (en) 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
WO2008094200A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US9439959B2 (en) 2006-07-27 2016-09-13 Takeda Vaccines, Inc. Chimeric influenza virus-like particles
US20090081193A1 (en) * 2006-08-14 2009-03-26 Massachusetts Institute Of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
US20080241918A1 (en) * 2006-08-14 2008-10-02 Ram Sasisekharan Hemagglutinin polypeptides, and reagents and methods relating thereto
US20090269342A1 (en) 2006-08-14 2009-10-29 Massachusetts Institute Of Technology Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
WO2008040060A1 (en) 2006-10-04 2008-04-10 The University Of Queensland Vlp based vaccine delivery system
US20080233150A1 (en) 2006-11-16 2008-09-25 Gale Smith Respiratory syncytial virus-virus like particle (vlps)
WO2008148104A1 (en) 2007-05-25 2008-12-04 Novavax, Inc. Novel vlps derived from cells that do not express a viral matrix or core protein
CA2615372A1 (en) 2007-07-13 2009-01-13 Marc-Andre D'aoust Influenza virus-like particles (vlps) comprising hemagglutinin
HUE025702T2 (en) 2007-07-19 2016-04-28 Novavax Inc Avian Flu Chimeric VLPs
CA2711330A1 (en) 2008-01-03 2009-07-16 Massachusetts Institute Of Technology Decoy influenza therapies
MX370690B (es) 2008-07-18 2019-12-19 Medicago Inc Epitopo de inmunizacion de nuevo virus de la influenza.
US9278998B2 (en) 2009-07-02 2016-03-08 Massachusetts Institute Of Technology Compositions and methods for diagnosing and/or treating influenza infection

Also Published As

Publication number Publication date
AU2010266129A1 (en) 2012-02-02
US9709567B2 (en) 2017-07-18
JP2012532117A (ja) 2012-12-13
EP2448596A4 (en) 2013-02-20
US20110033490A1 (en) 2011-02-10
US20160266117A1 (en) 2016-09-15
WO2011003100A3 (en) 2011-02-24
AU2010266129B2 (en) 2016-04-14
JP2016028107A (ja) 2016-02-25
WO2011003100A2 (en) 2011-01-06
ES2566361T3 (es) 2016-04-12
JP5886194B2 (ja) 2016-03-16
EP2448596A2 (en) 2012-05-09
WO2011003100A4 (en) 2011-04-14
CA2766899A1 (en) 2011-01-06
EP2448596B1 (en) 2016-01-06
US9278998B2 (en) 2016-03-08

Similar Documents

Publication Publication Date Title
CA2766899C (en) Compositions and methods for diagnosing and/or treating influenza infection
US20190142931A1 (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
AU2011305371B2 (en) Human-adapted HA polypeptides, vaccines, and influenza treatment
AU2007332987A1 (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
EP2953967B1 (en) Human adaptation of h5 influenza
US20090269342A1 (en) Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
US20160130306A1 (en) Human Adaptation of H7 HA
CA2711334A1 (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
HK1218923B (en) Human adaptation of h5 influenza

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150702

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 15TH ANNIV.) - STANDARD

Year of fee payment: 15

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250627

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250627